Mon panier

ALK-1

ALK-1 Informations sur la molécule

Nom anglaisActivin receptor-like kinase 1Nombre de médicaments commercialisés0
Nombre de médicaments cliniques1Alias de la cibleEC:2.7.11.30,ACVRLK1,Activin A Receptor Type II-Like 1,Activin A Receptor, Type II-Like Kinase 1,EC 2.7.11,ALK-1,Serine/threonine-protein kinase receptor R3,TGF-B superfamily receptor type I,Activin receptor-like kinase 1,SKR3,ALK1,ACVRL1,Activin A Receptor Like Type 1,Activin A Receptor Type IL,TSR-I,EC 2.7.11.30,HHT2,ORW2,HHT
Phase de R&D la plus avancéePhase 2 Clinical
Nom anglaisActivin receptor-like kinase 1
Alias de la cibleEC:2.7.11.30,ACVRLK1,Activin A Receptor Type II-Like 1,Activin A Receptor, Type II-Like Kinase 1,EC 2.7.11,ALK-1,Serine/threonine-protein kinase receptor R3,TGF-B superfamily receptor type I,Activin receptor-like kinase 1,SKR3,ALK1,ACVRL1,Activin A Receptor Like Type 1,Activin A Receptor Type IL,TSR-I,EC 2.7.11.30,HHT2,ORW2,HHT
Nombre de médicaments commercialisés0
Nombre de médicaments cliniques1
Phase de R&D la plus avancéePhase 2 Clinical

ALK-1 Liste de produits

  • Attribut

    Protein (1)

  • Bibliothèque de produits

    En ligne (1)

  • Espèces

    Human (1)

  • Étiquette

    His Tag (1)

  • Marqueur

    Unconjugated (1)

Numéro de produitEspècesSystème d'expressionDescription du produitStructure protéiquePuretéCaractéristiquesPré-commande/Commande
AL1-H5228
Human
HEK293
Human ALK-1 / ACVRL1 Protein, His Tag, low endotoxin (MALS verified)
Ajouter au panier
Quantité totale1
  • 1

ALK-1Contexte de la molécule

Serine/threonine-protein kinase receptor R3 is an enzyme that in humans is encoded by the ALK1 gene. ALK1 is a receptor in the TGF beta signaling pathway. ALK1 protein is a receptor in the TGF beta signaling pathway. It plays an important role in vascular development, remodeling, and pathologic angiogenesis, play a role in stabilizing angiogenic vessels and contribute to resistance to anti-VEGF therapies, ALK1 blockade may represent an effective therapeutic opportunity complementary to the current antiangiogenic modalities in the clinic. Recently, researcher found that, ALK1-Fc inhibited BMP9-mediated Id-1 expression in human umbilical vein endothelial cells and inhibited cord formation by these cells on a Matrigel substrate, in a chick chorioallantoic membrane assay, ALK1-Fc reduced vascular endothelial growth factor-, fibroblast growth factor-, and BMP10-mediated vessel formation, and ALK1-Fc treatment reduced tumor burden in mice receiving orthotopic grafts of MCF7 mammary adenocarcinoma cells.

ALK-1Alias de la molécule

ACVRL1,ACVRLK1,ALK-1,HHT,HHT2,ORW2,SKR3,TSR-I

Informations sur les médicaments cliniques

Nom anglaisCode de recherchePhase de R&DEntrepriseIndicationEssai clinique
AscrinvacumabPF-3446962; GT-90001; PF-3-446-962; GT-90001C; ALK-1; GT90001C; PF-03446962Phase 2 ClinicalPfizer IncCarcinoma, Hepatocellular; Colorectal Neoplasms; Liver Neoplasms; Macular Degeneration; Mesothelioma; Neoplasms; Solid tumours
Details
  • Informations sur la molécule
  • Liste de produits
  • Informations sur les médicaments cliniques